KLRK1 and ovarian cancer: Similarly, romidepsin, an HDACi, has been utilized to enhance the expression of NKG2D ligands (NKG2DL), such as MICA/MICB, on ovarian cancer cells, thereby improving the efficacy of NKG2DL-targeting CAR T-cells.